Pyruvate kinase M2 (PKM-2) expression and prognostic significance in glioblastoma patients

Basit Öğe Kaydı
dc.contributor.authorYavuz, Berrin Benli
dc.contributor.authorKilinc, Fahriye
dc.contributor.authorKanyilmaz, Gul
dc.contributor.authorAktan, Meryem
dc.date.accessioned2024-02-23T13:59:24Z
dc.date.available2024-02-23T13:59:24Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractPurposePyruvate kinase M2 (PKM2) is a key enzyme that catalyzes the irreversible and final step of glycolysis. It is closely associated with cancer development and progression. The relationship between PKM2 and prognosis in glioblastoma (GB) patients is unknown. The aim of this study was to measure PKM2 expression and evaluate its effect on prognosis in GB patients.MethodsPatients who underwent radiotherapy (RT) for glioblastoma between 2010 and 2021 were evaluated immunohistochemically. A single pathologist evaluated pathology specimens of all patients. The intensity and extent of staining of tumor cells were scored. Patients were categorized as low and high PKM2.ResultsA total of 119 patients were evaluated. While 80.7% of the cases had a low score, 19.3% had a high PKM2 score. It was observed that the group with high PKM2 expression had lower performance, received more hypofractionated RT and received adjuvant chemotherapy (CT) less frequently. Median overall survival (OS) was 15.77 months in the low PKM2 expression group and 6.50 months in the high PKM2 group. In univariate analyses, PKM2 expression, age, performance status, type of surgery, RT scheme, and concurrent and adjuvant CT were prognostic factors in predicting OS. In multivariate analyses, PKM2 expression, type of surgery, RT scheme and receiving adjuvant CT were prognostic factors for OS.ConclusionPKM2 is an independent prognostic factor for survival and is associated with poor prognosis in GBM patients treated with radiotherapy. It may be a potential therapeutic target for anticancer therapy.en_US
dc.description.sponsorshipScientific and Research Council of Necmettin Erbakan University [221218006]en_US
dc.description.sponsorshipThis project was supported by the Scientific and Research Council of Necmettin Erbakan University, Project Number: 221218006.en_US
dc.identifier.doi10.1007/s11060-023-04521-1
dc.identifier.issn0167-594X
dc.identifier.issn1573-7373
dc.identifier.pmid38010491en_US
dc.identifier.scopus2-s2.0-85178163336en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1007/s11060-023-04521-1
dc.identifier.urihttps://hdl.handle.net/20.500.12452/11169
dc.identifier.wosWOS:001113307600001en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal Of Neuro-Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPiruvat Kinaz M2en_US
dc.subjectGlioblastomaen_US
dc.subjectPrognosisen_US
dc.subjectRadiotherapyen_US
dc.titlePyruvate kinase M2 (PKM-2) expression and prognostic significance in glioblastoma patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu